BioMimetic Therapeutics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

November 2024 | 50 pages | ID: B9C1CEE81B4BEN
BAC Reports

Abstracts

BioMimetic Therapeutics Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between BioMimetic Therapeutics Inc. and its competitors. This provides our Clients with a clear understanding of BioMimetic Therapeutics Inc. position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about BioMimetic Therapeutics Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for BioMimetic Therapeutics Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The BioMimetic Therapeutics Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes BioMimetic Therapeutics Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of BioMimetic Therapeutics Inc. business.

About BioMimetic Therapeutics Inc.

BioMimetic Therapeutics, Inc., a biotechnology company, develops and commercializes products to help stimulate the body’s natural tissue regenerative process. Its protein therapeutic-device combination products improve the treatment of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage.

The company’s platform regenerative technology, which incorporates a potent version of one of the body’s natural key stimulators of tissue repair, may offer physicians advanced biological solutions to actively stimulate tissue healing and regeneration. Its product candidates are designed to target a range of clinical indications in bone, ligament, tendon, and cartilage repair.

Product Candidates

The company’s advanced product candidates are targeted to be used in the open surgical treatment of fractures and fusions (using Augment Bone Graft (Augment)) and the closed non-surgical or minimally invasive treatment of fractures (using Augment Injectable Bone Graft (Augment Injectable)). The company’s product candidates use recombinant human Platelet-Derived Growth Factor (rhPDGF-BB), which is a wound healing stimulatos, to kick start the tissue regeneration process in the body.

Augment Bone Graft for Orthopedic and Spine Indications

Open (surgical) Treatment of Fractures/Fusions: The company is evaluating Augment in various open clinical applications, including foot and ankle fusions and distal radius fractures. It has received clearance under the trade name OsteoMimetic for a proprietary §-TCP, which is a component of its Augment product candidate, for orthopedic applications as a bone void filler when the void or gap is not intrinsic to the stability of the bone.

Closed (non-surgical) Treatment of Fractures: The company has developed Augment Injectable for the surgical treatment of fractures, as well as the treatment of fractures not requiring surgery. Augment Injectable combines rhPDGF with an injectable bone matrix consisting of §-TCP and collagen.

Product Candidates for Sports Injuries

The company is using its platform technology to develop product candidates which address unmet medical needs in sports injury applications by targeting cartilage, ligament and tendon repair and regeneration. rhPDGF has been documented as a potent mitogen for cell types impacted by these injuries (tenocytes and chondrocytes) and, when delivered appropriately, rhPDGF can induce increases in vascularity (angiogenesis), cell proliferation (mitogenesis), and cell recruitment (chemotaxis). Its products Augment C to treat cartilage repair; Augment RC for rotator cuff tendon to bone repair; Augment AT for the treatment of acute tendon injuries; and Augment CT for chronic tendon injuries.

Suppliers

The company has supply agreement with Novartis covering the bioactive component of its product candidates, rhPDGF.

Competition

Augment: The company's competitors include orthopedic companies in the United States, such as Stryker Corporation; DePuy Orthopaedics, Inc. (a subsidiary of Johnson & Johnson); Zimmer Holdings, Inc.; Medtronic; Synthes, Inc.; Biomet, Inc.; Smith & Nephew Group plc; and Wright Medical Group, Inc. It also competes with tissue processors and procurement agencies, such as Osteotech, Inc., the Musculoskeletal Transplant Foundation (MTF) Regeneration Technologies, Inc., LifeCell Corporation, and CryoLife, Inc.

Cartilage, Ligament, and Tendon: The company identifies competition from Genzyme Tissue Repair.

History

The company was founded in 1999. It was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in 2005.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. BIOMIMETIC THERAPEUTICS INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. BIOMIMETIC THERAPEUTICS INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. BIOMIMETIC THERAPEUTICS INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. BIOMIMETIC THERAPEUTICS INC. FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. BIOMIMETIC THERAPEUTICS INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. BioMimetic Therapeutics Inc. Direct Competitors
5.2. Comparison of BioMimetic Therapeutics Inc. and Direct Competitors Financial Ratios
5.3. Comparison of BioMimetic Therapeutics Inc. and Direct Competitors Stock Charts
5.4. BioMimetic Therapeutics Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. BioMimetic Therapeutics Inc. Industry Position Analysis

6. BIOMIMETIC THERAPEUTICS INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. BIOMIMETIC THERAPEUTICS INC. EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. BIOMIMETIC THERAPEUTICS INC. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. BIOMIMETIC THERAPEUTICS INC. IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. BIOMIMETIC THERAPEUTICS INC. PORTER FIVE FORCES ANALYSIS²

12. BIOMIMETIC THERAPEUTICS INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

BioMimetic Therapeutics Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
BioMimetic Therapeutics Inc. 1-year Stock Charts
BioMimetic Therapeutics Inc. 5-year Stock Charts
BioMimetic Therapeutics Inc. vs. Main Indexes 1-year Stock Chart
BioMimetic Therapeutics Inc. vs. Direct Competitors 1-year Stock Charts
BioMimetic Therapeutics Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

BioMimetic Therapeutics Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
BioMimetic Therapeutics Inc. Key Executives
BioMimetic Therapeutics Inc. Major Shareholders
BioMimetic Therapeutics Inc. History
BioMimetic Therapeutics Inc. Products
Revenues by Segment
Revenues by Region
BioMimetic Therapeutics Inc. Offices and Representations
BioMimetic Therapeutics Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
BioMimetic Therapeutics Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
BioMimetic Therapeutics Inc. Capital Market Snapshot
BioMimetic Therapeutics Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
BioMimetic Therapeutics Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
BioMimetic Therapeutics Inc. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?